Pharmaceutical major Lupin has entered into a strategic partnership with Sandoz to market and distribute its biosimilar Ranibizumab in select global markets. Ranibizumab, a widely prescribed treatment for retinal disorders such as age-related macular degeneration and diabetic macular edema, represents a high-value segment within the ophthalmology therapeutics market. This collaboration combines Lupin’s manufacturing expertise with Sandoz’s extensive global commercial network, aiming to broaden patient access to advanced eye care solutions.